phrykt

Upstream Bio, Inc. (UPB): who owns it and who trades it

As of Nov 16, 2026, UPB insiders reported 15 open-market sales worth $105K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Everett Rand Sutherland (CEO), with $43.7K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Upstream Bio

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns UPB

148 funds and institutions reported UPB shares worth $352M at the end of Q2 2026, about 93% of the company. The largest holder is FMR LLC (Fidelity) with 15.0%.

Funds and institutions (13F) 93%Everyone else 7%

10 largest owners, by share of the company

FMR LLC (Fidelity)15.0%
Orbimed Advisors LLC10.5%
Norges Bank6.9%
BlackRock, Inc.6.9%
Decheng Capital LLC5.0%
Enavate Sciences Gp, LLC4.5%
Vanguard Capital Management LLC3.4%
Millennium Management LLC2.1%
D. E. Shaw & Co., Inc.1.9%
JPMorgan Chase & Co1.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)8.16M15.00%$56.5M+1%
Orbimed Advisors LLC5.69M10.46%$39.4MNo change
Norges Bank3.77M6.93%$26.1M–
BlackRock, Inc.3.75M6.90%$26M+11%
Decheng Capital LLC2.72M5.01%$18.9MNo change
Enavate Sciences Gp, LLC2.46M4.52%$17MNo change
Vanguard Capital Management LLC1.88M3.45%$13M+0%
Millennium Management LLC1.14M2.10%$7.9M+22%
D. E. Shaw & Co., Inc.1.04M1.90%$7.2M+26%
JPMorgan Chase & Co1.01M1.86%$7M–
Qube Research & Technologies Ltd978,5001.80%$6.8M+58%
Parkman Healthcare Partners LLC935,2471.72%$6.5M+19%
Geode Capital Management, LLC931,2611.71%$6.4M-2%
SEB Asset Management AB878,4731.61%$6.1MNo change
Woodline Partners LP831,4811.53%$5.8MNo change
State Street Corp766,3231.41%$5.3M+9%
Vanguard Portfolio Management LLC712,6671.31%$4.9M-2%
Y-Intercept (Hong Kong) Ltd693,5551.27%$4.8M-31%
Bain Capital Life Sciences Investors, LLC600,9491.10%$4.2M-31%
AQR Capital Management LLC544,8691.00%$3.8M+655%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, UPB insiders reported $0 of open-market purchases and $105K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$105K
15 trades, 5 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Sep 16, 2026
Filed Sep 17, 2026

Purchases and sales by month

$46.6K$46.6KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 16, 2026Aaron DeykinChief Medical OfficerSale895$5.49$4.9KForm 4
Sep 16, 2026Everett Rand SutherlandCEOSale2,095$5.49$11.5KForm 4
Sep 16, 2026Adam HoughtonChief Business OfficerSale700$5.49$3.8KForm 4
Sep 16, 2026Michael GrayCFOSale853$5.49$4.7KForm 4
Sep 16, 2026Allison AmbroseGeneral CounselSale485$5.49$2.7KForm 4
Jun 16, 2026Michael GrayCFOSale853$6.10$5.2KForm 4
Jun 16, 2026Everett Rand SutherlandCEOSale2,095$6.10$12.8KForm 4
Jun 16, 2026Adam HoughtonChief Business OfficerSale700$6.10$4.3KForm 4
Jun 16, 2026Aaron DeykinChief Medical OfficerSale895$6.10$5.5KForm 4
Jun 16, 2026Allison AmbroseGeneral CounselSale477$6.10$2.9KForm 4
Mar 16, 2026Michael GrayCFOSale852$9.29$7.9KForm 4
Mar 16, 2026Aaron DeykinChief Medical OfficerSale894$9.29$8.3KForm 4
Mar 16, 2026Everett Rand SutherlandCEOSale2,093$9.29$19.4KForm 4
Mar 16, 2026Allison AmbroseGeneral CounselSale475$9.29$4.4KForm 4
Mar 16, 2026Adam HoughtonChief Business OfficerSale699$9.29$6.5KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Everett Rand SutherlandChief Executive Officer, Director–$43.7KSep 16, 2026
Aaron DeykinChief Medical Officer–$18.7KSep 16, 2026
Michael GrayCFO and COO–$17.8KSep 16, 2026
Adam HoughtonChief Business Officer–$14.6KSep 16, 2026
Allison AmbroseGeneral Counsel–$10KSep 16, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

UPB short interest

Moderate short interest. 6.5% of UPB shares are sold short: about 1 share in 15. Over the last 12 reports the number of shares short went up 4%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.55M UPB shares were sold short, 6.5% of the shares outstanding, down 20.8% from the report before. At the average daily volume of 1.32M shares, buying them all back would take about 2.7 trading days (days to cover).

Shares short, % of all shares

6.48%May 15Oct 308.54%

Days to cover

2.7May 15Oct 309.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.55M6.48%-21%1.32M2.7
Oct 15, 20264.48M8.18%-1%1.22M3.7
Sep 30, 20264.51M8.24%+1%587,9667.7
Sep 15, 20264.49M8.20%+10%656,1926.8
Aug 31, 20264.10M7.48%+2%549,5037.5
Aug 14, 20264.02M7.33%+10%712,3935.6
Jul 31, 20263.65M6.70%+1%486,9617.5
Jul 15, 20263.62M6.65%-12%442,0988.2
Jun 30, 20264.11M7.54%+5%718,3385.7
Jun 15, 20263.90M7.16%+7%711,4765.5
May 29, 20263.64M6.69%+7%534,4046.8
May 15, 20263.40M6.24%+5%507,8126.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Upstream Bio company events

Upstream Bio filed 9 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Sep 1, 2026AnnouncementThe Company announced its pivotal Phase 3 development plans for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps. Filing
  3. Aug 11, 2026ResultsReleased financial results. Filing
  4. Jun 10, 2026VoteReported shareholder vote results. Filing
  5. May 13, 2026ResultsReleased financial results. Filing
  6. Mar 26, 2026AgreementUpstream Bio, Inc. entered into a Sales Agreement with Leerink Partners LLC, as sales agent, pursuant to which the Company from time to time may offer and sell shares of its common stock, par value $0.001 per share, through or to the Agent. Filing
  7. Mar 26, 2026ResultsReleased financial results. Filing
  8. Feb 11, 2026ResultsReleased financial results. Filing
  9. Feb 11, 2026AnnouncementThe Company announced positive top-line data from the Phase 2 global, randomized, double-blind, placebo-controlled, dose-ranging, parallel group VALIANT clinical trial (NCT06196879) that evaluated the safety and efficacy of verekitug for up to 60 weeks, with a minimum of 24 weeks of treatment, in… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Upstream Bio financials

Famous investors that hold UPB

5 of the 50 well-known investors we track reported holding UPB in their latest 13F filing. The largest position is Israel Englander's, worth $6.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20261.17M$6.2M0.0%+2%
Steve Cohen · Point72 Asset ManagementQ3 2026372,823$2M0.0%-18%
Jim Simons · Renaissance TechnologiesQ3 2026194,700$1M0.0%+48%
Ken Griffin · Citadel AdvisorsQ3 202659,042$311K0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202626,755$141K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named UPB in the last 120 days.

FiledHolderFormStake
Nov 6, 2026FMR LLC13G/A6.9%
Nov 6, 2026FMR LLC13G/A6.9%
Oct 29, 2026Decheng Capital Global Life Sciences Fund IV, L.P.13G/A4.9%
Oct 29, 2026Decheng Capital Global Life Sciences Fund IV, L.P.13G/A4.9%

Questions about Upstream Bio, Inc. (UPB) stock

Who owns the most UPB stock?

The largest reported owner of Upstream Bio, Inc. (UPB) is FMR LLC (Fidelity), with 15.0% of the company. In total, 148 funds and institutions reported holding UPB at the end of Q2 2026, together about 93% of the shares. See the largest owners.

Are UPB insiders buying or selling?

In the last 12 months, UPB insiders reported no open-market purchases and 15 sales worth $105K. The latest trade was on Sep 16, 2026. See every trade.

What is the short interest in UPB?

As of Oct 30, 2026, 3.55M UPB shares were sold short, 6.5% of the shares outstanding, down 20.8% from the report before. At the average daily volume of 1.32M shares, buying them all back would take about 2.7 trading days (days to cover). See the history.

Which famous investors hold UPB?

5 of the 50 well-known investors we track reported UPB in their latest 13F filing, including Israel Englander, Steve Cohen, Jim Simons. The largest position is worth $6.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.